Ther­a­cos­Bio aims to chal­lenge Big Phar­ma block­busters with new­ly-ap­proved SGLT2 for di­a­betes

Ther­a­cos­Bio is squar­ing up for its lit­tle-en­gine-that-could mo­ment. Its type 2 di­a­betes med Bren­zavvy nabbed FDA ap­proval on Fri­day, land­ing the pri­vate­ly-fund­ed, lit­tle-known biotech in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER